Tumor-promoting circuits that regulate a cancer-related chemokine cluster: Dominance of inflammatory mediators over oncogenic alterations

Cancers

Volumn 4, Issue 1, 2012, Pages 55-76

  Leibovich Rivkin, Tal ^a   Buganim, Yosef ^b   Solomon, Hilla ^b   Meshel, Tsipi ^a   Rotter, Varda ^b   Ben Baruch, Adit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Cluster of cancer related chemokines; IL 1 ; Inflammatory cytokines; P53 dysfunction; Ras hyper activation; TNF

Indexed keywords

CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN C JUN; PROTEIN P53; RANTES; RAS PROTEIN; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER RELAPSE; CLUSTER ANALYSIS; CYTOKINE RELEASE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFLAMMATORY DISEASE; MALIGNANT TRANSFORMATION; NATURAL KILLER CELL; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; TH1 CELL; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT; WESTERN BLOTTING;

EID: 84859029501     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers4010055     Document Type: Article

References (60)

1. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674.
2. Joyce, J.A.; Pollard, J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9, 239-252.
3. Milyavsky, M.; Tabach, Y.; Shats, I.; Erez, N.; Cohen, Y.; Tang, X.; Kalis, M.; Kogan, I.; Buganim, Y.; Goldfinger N.; et al. Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. Cancer Res. 2005, 65, 4530-4543.
4. Buganim, Y.; Solomon, H.; Rais, Y.; Kistner, D.; Nachmany, I.; Brait, M.; Madar, S.; Goldstein, I.; Kalo, E.; Adam, N., et al. p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways. Cancer Res. 2010, 70, 2274-2284.
5. Bonecchi, R.; Locati, M.; Mantovani, A. Chemokines and cancer: A fatal attraction. Cancer Cell 2011, 19, 434-435.
6. Lazennec, G.; Richmond, A. Chemokines and chemokine receptors: New insights into cancer-related inflammation. Trends Mol. Med. 2010, 16, 133-144.
7. Yadav, A.; Saini, V.; Arora, S.; MCP-1: Chemoattractant with a role beyond immunity: A review. Clin. Chim. Acta 2010, 411, 1570-1579.
8. Soria, G.; Ben-Baruch, A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 2008, 267, 271-285.
9. Conti, I.; Rollins, B.J. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin. Cancer Biol. 2004, 14, 149-154.
10. Waugh, D.J.; Wilson, C. The interleukin-8 pathway in cancer. Clin. Cancer Res. 2008, 14, 6735-6741.
11. Richmond, A.; Yang, J.; Su, Y. The good and the bad of chemokines/chemokine receptors in melanoma. Pigment Cell Melanoma Res. 2009, 22, 175-186.
12. Keeley, E.C.; Mehrad, B.; Strieter, R.M. CXC chemokines in cancer angiogenesis and metastases. Adv. Cancer Res.2010, 106, 91-111.
13. Keeley, E.C.; Mehrad, B.; Strieter, R.M. Chemokines as mediators of neovascularization. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 1928-1936.
14. Fulton, A.M. The chemokine receptors CXCR4 and CXCR3 in cancer. Curr. Oncol. Rep. 2009, 11, 125-131.
15. Ben-Baruch, A. Expert commentary: The chemokine receptor CXCR3 and its ligands in malignancy: Do they act as double-edged swords? In Chemokine Research Trends; Grinwald, L.R., Ed.; Nova Science Publishers: Hauppauge, NY, USA, 2007.
16. Karnoub, A.E.; Weinberg, R.A. Ras oncogenes: Split personalities. Nat. Rev. Mol. Cell Biol. 2008, 9, 517-531.
17. Schubbert, S.; Shannon, K.; Bollag, G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 2007, 7, 295-308.
18. Blum, R.; Cox, A.D.; Kloog, Y. Inhibitors of chronically active ras: Potential for treatment of human malignancies. Recent Pat. Anticancer Drug Discov. 2008, 3, 31-47.
19. Olivier, M.; Hollstein, M.; Hainaut, P. TP53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol. 2010, 2, a001008.
20. Goldstein, I.; Marcel, V.; Olivier, M.; Oren, M.; Rotter, V.; Hainaut, P. Understanding wild-type and mutant p53 activities in human cancer: New landmarks on the way to targeted therapies. Cancer Gene Ther. 2011, 18, 2-11.
21. Oren, M.; Rotter, V. Mutant p53 gain-of-function in cancer. Cold Spring Harb. Perspect. Biol. 2010, 2, a001107.
22. Toledo, F.; Bardot, B. Cancer: Three birds with one stone. Nature 2009, 460, 466-467.
23. Brosh, R.; Rotter, V. When mutants gain new powers: News from the mutant p53 field. Nat. Rev. Cancer 2009, 9, 701-713.
24. Balkwill, F. Tumour necrosis factor and cancer. Nat. Rev. Cancer 2009, 9, 361-371.
25. Balkwill, F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 2006, 25, 409-416.
26. ten Hagen, T.L.; Seynhaeve, A.L.; Eggermont, A.M. Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed. Immunol. Rev. 2008, 222, 299-315.
27. Mocellin, S.; Rossi, C.R.; Pilati, P.; Nitti, D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev. 2005, 16, 35-53.
28. Dinarello, C.A. Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev. 2010, 29, 317-329.
29. Apte, R.N.; Voronov, E. Is interleukin-1 a good or bad guy in tumor immunobiology and immunotherapy? Immunol. Rev. 2008, 222, 222-241.
30. Meylan, E.; Dooley, A.L.; Feldser, D.M.; Shen, L.; Turk, E.; Ouyang, C.; Jacks, T. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009, 462, 104-107.
31. Motohara, T.; Masuko, S.; Ishimoto, T.; Yae, T.; Onishi, N.; Muraguchi, T.; Hirao, A.; Matsuzaki, Y.; Tashiro, H.; Katabuchi, H., et al. Transient depletion of p53 followed by transduction of c-Myc and K-Ras converts ovarian stem-like cells into tumor-initiating cells. Carcinogenesis 2011, 32, 1597-1606.
32. Parada, L.F.; Land, H.; Weinberg, R.A.; Wolf, D.; Rotter, V. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature 1984, 312, 649-651.
33. Xia, M.; Land, H. Tumor suppressor p53 restricts Ras stimulation of RhoA and cancer cell motility. Nat. Struct. Mol. Biol. 2007, 14, 215-223.
34. Hahn, W.C.; Counter, C.M.; Lundberg, A.S.; Beijersbergen, R.L.; Brooks, M.W.; Weinberg, R.A. Creation of human tumour cells with defined genetic elements. Nature 1999, 400, 464-468.
35. Drayton, S.; Rowe, J.; Jones, R.; Vatcheva, R.; Cuthbert-Heavens, D.; Marshall, J.; Fried, M.; Peters, G. Tumor suppressor p16INK4a determines sensitivity of human cells to transformation by cooperating cellular oncogenes. Cancer Cell 2003, 4, 301-310.
36. Rangarajan, A.; Hong, S.J.; Gifford, A.; Weinberg, R.A. Species- and cell type-specific requirements for cellular transformation. Cancer Cell 2004, 6, 171-183.
37. Milyavsky, M.; Shats, I.; Erez, N.; Tang, X.; Senderovich, S.; Meerson, A.; Tabach, Y.; Goldfinger, N.; Ginsberg, D.; Harris, C.C., et al. Prolonged culture of telomerase-immortalized human fibroblasts leads to a premalignant phenotype. Cancer Res. 2003, 63, 7147-7157.
38. Solomon, H.; Brosh, R.; Buganim, Y.; Rotter, V. Inactivation of the p53 tumor suppressor gene and activation of the Ras oncogene: Cooperative events in tumorigenesis. Discov. Med. 2010, 9, 448-454.
39. Zlotnik, A. Involvement of chemokine receptors in organ-specific metastasis. Contrib. Microbiol. 2006, 13, 191-199.
40. Zlotnik, A. New insights on the role of CXCR4 in cancer metastasis. J. Pathol. 2008, 215, 211-213.
41. Su, H.; Sobrino Najul, E.J.; Toth, T.A.; Mei Ng, C.; Lelievre, S.A.; Fred, M.; Tang, C.K. Chemokine receptor CXCR4-mediated transformation of mammary epithelial cells by enhancing multiple RTKs expression and deregulation of the p53/MDM2 axis. Cancer Lett. 2011, 307, 132-140.
42. Bissell, M.J. Radisky, D. Putting tumours in context. Nat. Rev. Cancer 2001, 1, 46-54.
43. Creighton, C.J.; Bromberg-White, J.L.; Misek, D.E.; Monsma, D.J.; Brichory, F.; Kuick, R.; Giordano, T.J.; Gao, W.; Omenn, G.S.; Webb, C.P., et al. Analysis of tumor-host interactions by gene expression profiling of lung adenocarcinoma xenografts identifies genes involved in tumor formation. Mol. Cancer Res. 2005, 3, 119-129.
44. Talmadge, J.E.; Fidler, I.J. Enhanced metastatic potential of tumor cells harvested from spontaneous metastases of heterogeneous murine tumors. J. Natl. Cancer Inst. 1982, 69, 975-980.
45. Halachmi, E.; Witz, I.P. Differential tumorigenicity of 3T3 cells transformed in vitro with polyoma virus and in vivo selection for high tumorigenicity. Cancer Res. 1989, 49, 2383-2389.
46. Roebuck, K.A.; Carpenter, L.R.; Lakshminarayanan, V.; Page, S.M.; Moy, J.N.; Thomas, L.L. Stimulus-specific regulation of chemokine expression involves differential activation of the redox-responsive transcription factors AP-1 and NF-kappaB. J. Leukoc. Biol. 1999, 65, 291-298.
47. Murugan, V.; Peck, M.J. Signal transduction pathways linking the activation of alveolar macrophages with the recruitment of neutrophils to lungs in chronic obstructive pulmonary disease. Exp. Lung Res. 2009, 35, 439-485.
48. Adcock, I.M. Transcription factors as activators of gene transcription: AP-1 and NF-kappa B. Monaldi Arch. Chest Dis. 1997, 52, 178-186.
49. Baeuerle, P.A.; Henkel, T. Function and activation of NF-kappa B in the immune system. Annu. Rev. Immunol. 1994, 12, 141-179.
50. Ueda, A.; Ishigatsubo, Y.; Okubo, T.; Yoshimura, T. Transcriptional regulation of the human monocyte chemoattractant protein-1 gene. Cooperation of two NF-kappaB sites and NF-kappaB/Rel subunit specificity. J. Biol. Chem. 1997, 272, 31092-31099.
51. Martin, T.; Cardarelli, P.M.; Parry, G.C.; Felts, K.A.; Cobb, R.R. Cytokine induction of monocyte chemoattractant protein-1 gene expression in human endothelial cells depends on the cooperative action of NF-kappa B and AP-1. Eur. J. Immunol. 1997, 27, 1091-1097.
52. Mantovani, A.; Bonecchi, R.; Locati, M. Tuning inflammation and immunity by chemokine sequestration: Decoys and more. Nat. Rev. Immunol. 2006, 6, 907-918.
53. Rot, A.; von Andrian, U.H. Chemokines in innate and adaptive host defense: Basic chemokinese grammar for immune cells. Annu. Rev. Immunol. 2004, 22, 891-928.
54. Zlotnik, A.; Yoshie, O.; Nomiyama, H. The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol. 2006, 7, 243.
55. Sedgwick, J.D.; Riminton, D.S.; Cyster, J.G.; Korner, H. Tumor necrosis factor: A master-regulator of leukocyte movement. Immunol. Today 2000, 21, 110-113.
56. Furuichi, K.; Wada, T.; Iwata, Y.; Kokubo, S.; Hara, A.; Yamahana, J.; Sugaya, T.; Iwakura, Y.; Matsushima, K.; Asano, M., et al. Interleukin-1-dependent sequential chemokine expression and inflammatory cell infiltration in ischemia-reperfusion injury. Crit. Care Med. 2006, 34, 2447-2455.
57. Soria, G.; Ofri-Shahak, M.; Haas I.; Yaal-Hahoshen, N.; Leider-Trejo, L.; Leibovich-Rivkin, T.; Weitzenfeld, P.; Meshel, T.; Shabtai, E.; Gutman, M., et al. Inflammatory mediators in breast cancer: Coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer 2011, 11, 130-149.
58. Madhusudan, S.; Foster, M.; Muthuramalingam, S.R.; Braybrooke, J.P.; Wilner, S.; Kaur, K.; Han, C.; Hoare, S.; Balkwill, F.; Talbot, D.C., et al. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin. Cancer Res. 2004, 10, 6528-6534.
59. Brown, E.R.; Charles, K.A.; Hoare, S.A.; Rye, R.L.; Jodrell, D.I.; Aird, R.E.; Vora, R.; Prabhakar, U.; Nakada, M.; Corringham, R.E., et al. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann. Oncol. 2008, 19, 1340-1346.
60. Harrison, M.L.; Obermueller, E.; Maisey, N.R.; Hoare, S.; Edmonds, K.; Li, N.F.; Chao, D.; Hall, K.; Lee, C.; Timotheadou, E., et al. Tumor necrosis factor alpha as a new target for renal cell carcinoma: Two sequential phase II trials of infliximab at standard and high dose. J. Clin. Oncol. 2007, 25, 4542-4549.